GlassScriptPhysician profile
John J Paulowski
NPI 1841279684
$2,613.80
in general payments reported to CMS, 2019-2025
27 companies · $457 in 2025
The $457 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $670 · 2020: $138 · 2021: $182 · 2022: $601 · 2023: $404 · 2024: $162 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,023.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,022.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $634.96 | 2019-2025 | General - Therapies, Avvigo Guidance System, Rotapro |
| Medtronic, INC. | $428.58 | 2022-2025 | Symplicity G3, Intellis Adaptivestim |
| Cardiva Medical, INC. | $316.05 | 2019-2025 | Cardiva Vascade 6/7f Vcs |
| Abiomed | $290.03 | 2022-2024 | Impella |
| Amgen INC. | $164.47 | 2019-2023 | Repatha |
| Novartis Pharmaceuticals Corporation | $146.15 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $121.02 | 2019-2024 | Wainua |
| Terumo Medical Corporation | $60.06 | 2022 | |
| Sanofi-Aventis U.S. LLC | $55.04 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $42.61 | 2019-2020 | |
| Bridgebio Pharma, INC. | $38.72 | 2025 | Attruby |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $36.58 | 2019-2023 | Lifevest |
| Lundbeck LLC | $35.32 | 2019 | |
| Abbott Laboratories | $34.39 | 2019-2024 | Cardiomems |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.30 | 2020-2023 | Jardiance |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $23.69 | 2019 | |
| Genzyme Corporation | $23.55 | 2019 | |
| Merck Sharp & Dohme LLC | $20.90 | 2023 | Verquvo |
| Amarin Pharma, INC. | $18.61 | 2019 | |
| Teleflex LLC | $15.65 | 2025 | Guideliner |
| E.R. Squibb & Sons, L.L.C. | $14.96 | 2020 | |
| Cordis US Corp. | $14.32 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $13.67 | 2019 | |
| Cardiovascular Systems INC. | $13.56 | 2021 | |
| Astellas Pharma US INC | $13.43 | 2019 | |
| Z-Medica, LLC | $8.18 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Paulowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.